Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.
New research highlights strong associations between metabolic syndrome and several oral diseases—including periodontitis, caries, and peri-implantitis—calling for more longitudinal studies to explore causation and improve patient care.
GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.
A new imaging study found that patients who develop joint pain after cancer immunotherapy often show significant inflammation and joint damage on MRI—even when physical signs of arthritis are absent.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A review of nearly 300 idiopathic diabetes cases found that about 30% of patients had undiagnosed genetic mutations, raising concerns about misclassification and underuse of comprehensive genetic testing.
A large UK study of more than 336,000 adults found that central body fat, especially around the abdomen, was strongly linked to a higher risk of psoriasis, with the association more pronounced in women and independent of genetic risk.
A national survey found wide variation in intralesional corticosteroid injection techniques among US hair specialists treating different types of alopecia.
Genetic deletion of STING in a mouse model of Alzheimer’s disease reduced amyloid plaque accumulation, suppressed neuroinflammatory responses, and improved memory, highlighting STING’s role in disease progression and potential as a therapeutic target.